Changes in urinary Cu, Zn, and Se levels in cancer patients after treatment with Sha Shen Mai Men Dong Tang

Tung-Iuan Lai, Hsien Wen Kuo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sha Shen Mai Men Dong Tang (SMD-2; shā shěn mài dōng tāng) is a Chinese medicinal herb (CMH; zhōng čo yào) used to treat symptoms associated with cancer therapy. The objective of this study was to assess the effect of SMD-2 on the levels of urinary copper (Cu), zinc (Zn), and selenium (Se) in lung cancer patients and head and neck cancer patients receiving chemoradiotherapy. Forty-two head and neck cancer patients and 10 lung cancer patients participated in our clinical trial. Each patient received chemoradiotherapy for 4 weeks. In addition, each patient was treated with SMD-2 for 8 weeks, including 2 weeks prior to and after the chemoradiotherapy treatment. Comparison of urinary Cu, Zn, and Se levels and the ratios of Zn to Cu and Se to Cu at three time points in the two types of cancer were assessed using the generalized estimating equations (GEEs). After the patients received chemoradiotherapy for 4 weeks, SMD-2 treatment was found to be associated with a significant decrease in urinary Cu levels, whereas urinary Zn and Se levels increased significantly. In addition, the ratios of Zn to Cu and Se to Cu in the urine samples of these patients also increased significantly. Both the urinary Zn levels and the ratio of Zn to Cu in head and neck cancer patients were significantly higher than in lung cancer patients. Urinary Zn and Se levels and the ratios of Zn to Cu and Se to Cu, but not urinary Cu levels, increased significantly during and after treatment when assessed using the GEE model. The SMD-2 treatments significantly increased Zn and Se levels in the urine of head and neck cancer patients. Increased Zn and Se levels in urine strengthened immune system.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalJournal of Traditional and Complementary Medicine
Volume6
Issue number2
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Selenium
Zinc
Head and Neck Neoplasms
Neoplasms
Chemoradiotherapy
Therapeutics
Lung Neoplasms
Urine
fructus schizandrae, radix ginseng, radix ophiopogonis drug combination
Second Primary Neoplasms
Medicinal Plants
Copper
Immune System
Clinical Trials

Keywords

  • chemoradiotherapy
  • head and neck cancer patients
  • ratio of Se to Cu
  • ratio of Zn to Cu
  • urine

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

Changes in urinary Cu, Zn, and Se levels in cancer patients after treatment with Sha Shen Mai Men Dong Tang. / Lai, Tung-Iuan; Kuo, Hsien Wen.

In: Journal of Traditional and Complementary Medicine, Vol. 6, No. 2, 01.04.2016, p. 135-139.

Research output: Contribution to journalArticle

@article{d67282e16e614bd4999abf2d80fd2350,
title = "Changes in urinary Cu, Zn, and Se levels in cancer patients after treatment with Sha Shen Mai Men Dong Tang",
abstract = "Sha Shen Mai Men Dong Tang (SMD-2; shā shěn m{\`a}i dōng tāng) is a Chinese medicinal herb (CMH; zhōng čo y{\`a}o) used to treat symptoms associated with cancer therapy. The objective of this study was to assess the effect of SMD-2 on the levels of urinary copper (Cu), zinc (Zn), and selenium (Se) in lung cancer patients and head and neck cancer patients receiving chemoradiotherapy. Forty-two head and neck cancer patients and 10 lung cancer patients participated in our clinical trial. Each patient received chemoradiotherapy for 4 weeks. In addition, each patient was treated with SMD-2 for 8 weeks, including 2 weeks prior to and after the chemoradiotherapy treatment. Comparison of urinary Cu, Zn, and Se levels and the ratios of Zn to Cu and Se to Cu at three time points in the two types of cancer were assessed using the generalized estimating equations (GEEs). After the patients received chemoradiotherapy for 4 weeks, SMD-2 treatment was found to be associated with a significant decrease in urinary Cu levels, whereas urinary Zn and Se levels increased significantly. In addition, the ratios of Zn to Cu and Se to Cu in the urine samples of these patients also increased significantly. Both the urinary Zn levels and the ratio of Zn to Cu in head and neck cancer patients were significantly higher than in lung cancer patients. Urinary Zn and Se levels and the ratios of Zn to Cu and Se to Cu, but not urinary Cu levels, increased significantly during and after treatment when assessed using the GEE model. The SMD-2 treatments significantly increased Zn and Se levels in the urine of head and neck cancer patients. Increased Zn and Se levels in urine strengthened immune system.",
keywords = "chemoradiotherapy, head and neck cancer patients, ratio of Se to Cu, ratio of Zn to Cu, urine",
author = "Tung-Iuan Lai and Kuo, {Hsien Wen}",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.jtcme.2014.12.004",
language = "English",
volume = "6",
pages = "135--139",
journal = "Journal of Traditional and Complementary Medicine",
issn = "2225-4110",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Changes in urinary Cu, Zn, and Se levels in cancer patients after treatment with Sha Shen Mai Men Dong Tang

AU - Lai, Tung-Iuan

AU - Kuo, Hsien Wen

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Sha Shen Mai Men Dong Tang (SMD-2; shā shěn mài dōng tāng) is a Chinese medicinal herb (CMH; zhōng čo yào) used to treat symptoms associated with cancer therapy. The objective of this study was to assess the effect of SMD-2 on the levels of urinary copper (Cu), zinc (Zn), and selenium (Se) in lung cancer patients and head and neck cancer patients receiving chemoradiotherapy. Forty-two head and neck cancer patients and 10 lung cancer patients participated in our clinical trial. Each patient received chemoradiotherapy for 4 weeks. In addition, each patient was treated with SMD-2 for 8 weeks, including 2 weeks prior to and after the chemoradiotherapy treatment. Comparison of urinary Cu, Zn, and Se levels and the ratios of Zn to Cu and Se to Cu at three time points in the two types of cancer were assessed using the generalized estimating equations (GEEs). After the patients received chemoradiotherapy for 4 weeks, SMD-2 treatment was found to be associated with a significant decrease in urinary Cu levels, whereas urinary Zn and Se levels increased significantly. In addition, the ratios of Zn to Cu and Se to Cu in the urine samples of these patients also increased significantly. Both the urinary Zn levels and the ratio of Zn to Cu in head and neck cancer patients were significantly higher than in lung cancer patients. Urinary Zn and Se levels and the ratios of Zn to Cu and Se to Cu, but not urinary Cu levels, increased significantly during and after treatment when assessed using the GEE model. The SMD-2 treatments significantly increased Zn and Se levels in the urine of head and neck cancer patients. Increased Zn and Se levels in urine strengthened immune system.

AB - Sha Shen Mai Men Dong Tang (SMD-2; shā shěn mài dōng tāng) is a Chinese medicinal herb (CMH; zhōng čo yào) used to treat symptoms associated with cancer therapy. The objective of this study was to assess the effect of SMD-2 on the levels of urinary copper (Cu), zinc (Zn), and selenium (Se) in lung cancer patients and head and neck cancer patients receiving chemoradiotherapy. Forty-two head and neck cancer patients and 10 lung cancer patients participated in our clinical trial. Each patient received chemoradiotherapy for 4 weeks. In addition, each patient was treated with SMD-2 for 8 weeks, including 2 weeks prior to and after the chemoradiotherapy treatment. Comparison of urinary Cu, Zn, and Se levels and the ratios of Zn to Cu and Se to Cu at three time points in the two types of cancer were assessed using the generalized estimating equations (GEEs). After the patients received chemoradiotherapy for 4 weeks, SMD-2 treatment was found to be associated with a significant decrease in urinary Cu levels, whereas urinary Zn and Se levels increased significantly. In addition, the ratios of Zn to Cu and Se to Cu in the urine samples of these patients also increased significantly. Both the urinary Zn levels and the ratio of Zn to Cu in head and neck cancer patients were significantly higher than in lung cancer patients. Urinary Zn and Se levels and the ratios of Zn to Cu and Se to Cu, but not urinary Cu levels, increased significantly during and after treatment when assessed using the GEE model. The SMD-2 treatments significantly increased Zn and Se levels in the urine of head and neck cancer patients. Increased Zn and Se levels in urine strengthened immune system.

KW - chemoradiotherapy

KW - head and neck cancer patients

KW - ratio of Se to Cu

KW - ratio of Zn to Cu

KW - urine

UR - http://www.scopus.com/inward/record.url?scp=84939189943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939189943&partnerID=8YFLogxK

U2 - 10.1016/j.jtcme.2014.12.004

DO - 10.1016/j.jtcme.2014.12.004

M3 - Article

AN - SCOPUS:84939189943

VL - 6

SP - 135

EP - 139

JO - Journal of Traditional and Complementary Medicine

JF - Journal of Traditional and Complementary Medicine

SN - 2225-4110

IS - 2

ER -